AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Xspray Pharma Share Issue/Capital Change 2025

Sep 30, 2025

3129_rns_2025-09-30_2eb67639-3b5c-458a-b542-9b37f3361147.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

New number of shares and votes in Xspray Pharma after new share issue

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that the number of shares and votes in Xspray Pharma AB has changed. New shares have been issued as a result of the rights issue and over-allotment issue announced on August 15, 2025. On September 11, 2025, the Board of Directors also decided to increase the over-allotment issue due to the high subscription rate. Overall, the number of outstanding shares and votes has increased by 4,603,849 shares to a total of 41,742,340 shares and the share capital has increased by SEK 4,603,849 to SEK 41,742,340.

For more information, please contact:

Jacob Nyberg, IR Xspray Pharma AB (publ) Mob: +46 (0) 70 767 08 83 E-mail: [email protected]

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development utilizing its innovative, patented HyNap™ technology platform to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology market segment, often with high drug prices. The Company's goal is to become the market leader in improved PKI's for cancer treatment. Xspray Pharma's lead drug candidate, Dasynoc®, is currently undergoing FDA review. It is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose due to a better solubility profile. Its compatibility with proton pump inhibitors (PPIs), which are often co-prescribed to patients with CML and ALL, is a significant advantage. Xspray Pharma is building a robust product portfolio, including XS003 nilotinib (an optimized version of Tasigna®) and XS008-axitinib (an optimized version of Inlyta®) and XS025-cabozantinib (an optimized version of Cabometyx®).

The Xspray Pharma AB-share is trading at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).

www.xspraypharma.com.

This information is information that Xspray Pharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025- 09-30 15:55 CEST.

Attachments